Isomorphic raises $2.1B to push AI-designed drugs toward clinic

DeepMind spinout Isomorphic Labs raised $2.1 billion as Demis Hassabis now points to first AI-designed drugs entering human trials by late 2026.

무엇이 달라졌나

The company uses IsoDDE, a pipeline combining structure prediction, molecule generation, binding prediction and ADMET assessment.

Thrive, Alphabet-linked funds, MGX, Temasek and a UK sovereign AI fund joined the round, showing the capital intensity of AI drug discovery.

왜 중요한가

Entering clinical trials is not the same as approval; the pharmaceutical probability game remains slow and harsh.

다음 관전점

봐야 할 지점은 headline number 자체가 아니라 제품, 계약, 플랫폼 전환이 다음 두 분기에도 반복될 수 있는지다.

출처: CocoLoop